Commercialization
- The Meaning of Meta-Analyses
-
Meta-analyses can play a role in advancing scientific knowledge
for any given drug. But if poorly designed or hastily conducted, they can be damaging for an approved medicine.
- Knocking on a Difficult Door
-
Selling to managed care organizations requires an entirely different approach than traditional pharmaceutical detailing.
- Same Difference
-
Across Europe, incentive programs have been designed, redesigned and implemented to encourage physicians to prescribe generic medications. Although the practice may help reduce costs, does it represent value for everyone?
- Access to Innovation
-
Ideally, pharmaceutical pricing provides an incentive for innovation and also makes quality medicines accessible to all. Achieving this delicate balance, however, is proving to be a difficult proposition.
- Choosing Words Wisely
-
Semiotics and the process of studying vocabulary has found a niche in the pharmaceutical industry.
- A Bridge Too Far
-
A tangled web of patients, profits, patents and politics makes compulsory licensing a perennial source of frustration for pharmaceutical manufacturers trying to protect their innovative discoveries.
- Special Delivery
-
Pharmaceutical companies are learning the importance of having well-trained, highly qualified specialty sales reps.
- Changing Tides
-
Pharmaceutical companies and academic institutions are looking for ways to offer continuing medical education programs free from conflicts of interest.
- Leveling the Field
-
As the U.K. experience has shown, proving the safety, efficacy and value of medications can be a murky affair.
- Fair Exchange
-
Parallel trade of pharmaceuticals in Europe offers minimal benefit to consumers and payers, but the practice may push product development to the United States and other countries where research dollars and less stringent regulations abound.
Web Exclusives
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.
- Evidence-Based Development and Smarter Sourcing
-
Jay Norman, president of Quintiles Consulting, discusses the changing landscape of drug development and suggests that better, evidence-based decisions, combined with smart sourcing strategies, will differentiate the future winners.